APA (7th ed.) Citation

A, C., B, M., J, M., B, E., FA, H., S, C., . . . M, M. (2021). Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. Clinical breast cancer, 21(1), 80. https://doi.org/10.1016/j.clbc.2020.09.014

Chicago Style (17th ed.) Citation

A, Chan, et al. "Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial." Clinical Breast Cancer 21, no. 1 (2021): 80. https://doi.org/10.1016/j.clbc.2020.09.014.

MLA (9th ed.) Citation

A, Chan, et al. "Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial." Clinical Breast Cancer, vol. 21, no. 1, 2021, p. 80, https://doi.org/10.1016/j.clbc.2020.09.014.